Publications by authors named "R Thuemmler"
Article Synopsis
- The study focused on the effects of sotagliflozin, a sodium-glucose co-transporter inhibitor, on heart failure and cardiovascular outcomes in participants with type 2 diabetes, analyzing data from nine randomized controlled trials involving over 15,000 patients.
- Results showed that sotagliflozin significantly reduced the risk of heart failure, stroke, and major adverse cardiovascular events (MACE), with the number needed to treat (NNT) being 20 for heart failure and 26 for MACE.
- Despite its effectiveness, the review faced limitations due to a high risk of bias, suggesting a need for more research comparing sotagliflozin with other SGLT2 inhibitors to
Hypoalbuminemia associates with poor acute ischemic stroke (AIS) outcomes. We hypothesised a non-linear relationship and aimed to systematically assess this association using prospective stroke data from the Norfolk and Norwich Stroke and TIA Register. Consecutive AIS patients aged ≥40 years admitted December 2003-December 2016 were included.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the renal safety profile and efficacy of sotagliflozin in type 1 and type 2 diabetes patients, focusing on those with or without existing renal issues.
- Fourteen randomized controlled trials involving over 17,500 participants were analyzed, finding no significant changes in renal function or urinary albumin levels due to sotagliflozin treatment.
- While the drug showed no adverse effects on kidney conditions, more research is necessary to fully understand its potential in preventing diabetic kidney disease.
Background: Diabetes Mellitus (DM) disproportionately affects racial minority groups and is a well-established risk factor for ischemic stroke and worse stroke outcomes. Whether racial disparities exist in acute outcomes of patients presenting with Acute Ischemic Stroke (AIS) and comorbid DM, including potential differences in the administration of evidence-based reperfusion therapy, remains unclear. We aimed to assess whether racial and sex differences exist in the acute outcomes and treatment of patients with DM presenting with AIS.
View Article and Find Full Text PDF